Overview of Randomized Trials of Systemic Adjuvant Therapy

  • Peter M. Ravdin
Part of the Cancer Treatment and Research book series (CTAR, volume 141)

Since the first edition of this text adjuvant therapy for early stage breast cancer has changed in several important ways.

Several trials have further elucidated the impact of adjuvant chemotherapy for breast cancer. Several trials have confirmed the promise of aromatase inhibitors for adjuvant endocrine therapy. A new targeted therapy, trastuzumab, has been shown to be highly effective as part of adjuvant therapy for HER2-positive breast cancer.An updated meta-analysis of the benefits of adjuvant therapy of breast cancer has appeared.

Because of these advances adjuvant therapy options available to women today are quite different than those of just 5 years ago.

The purpose of this chapter is to review where our current therapy options have succeeded and where adjuvant therapy options have limited effectiveness or other associated problems. As a starting point we will review the results of the most recently published EBCCTG meta-analysis.


Breast Cancer Adjuvant Chemotherapy Adjuvant Therapy Subset Analysis Adjuvant Tamoxifen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717, 2005.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Peter M. Ravdin
    • 1
  1. 1.Division of OncologyUniversity of Texas Health Sciences Center at San AntonioSan AntonioUSA

Personalised recommendations